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Abstract. Acromegaly is rarely caused by the ectopic secretion of growth hormone releasing factor (GRF) from peripheral neuroendocrine tumours. We evaluated the ability of a recently developed somatostatin analogue Sandoz) (Belmont, CA) . This assay has a lower limit of sensitivity, defined as 15% of maximum dis¬ placement, of 0.009 ng/ml. The normal range for plasma GRF is less than 0.02 ng/ml. GH (National Hormone and Pituitary Program, nor¬ mal < 10 ng/ml), gastrin (Becton-Dickinson, Orangeburg, NY, normal range < 100 pg/ml), insulin-like growth factor I (IGF-I, also known as somatomedin-C) (normal range 120 -244 ng/ml), and IGF-II (normal range 370-952 ng/ml) levels were determined by speci¬ fic radioimmunoassays (Wilson et al. 1982) .
Results
Mean hormone levels prior to therapy were 191 ng/ml for GH, 5.50 ng/ml for GRF, and 5025 pg/ml for gastrin. Immediately following initia¬ tion of a continuous intravenous infusion of 25 µg/h of SMS 201-995, levels of these hormones fell rapidly (Fig. 1) (Fig. 1) . Therapy was subsequently changed to a continuous sc infusion at a rate of 21 µg/h (500 µg/day) of SMS 201-995 using a portable infusion pump (Minimed, Pacesetter Systems, Inc., Sylmar, CA). During the first nine months of this therapy, there was a decrease in the mean levels of GH (19 ng/ml), GRF (1.14 ng/ml), and gastrin (1248 pg/ml). The variability in hormone levels, as measured by the standard deviation, was also decreased when compared with intermittent sc therapy (Fig. 2) Although gastrin levels remain elevated, the patient has been able to reduce her dose of ranitidine without any increase in her gastric discomfort. In addition, she has noted a drama¬ tic reduction in her other symptoms, including hyperhidrosis and fatigue. No side effects from the medication have been noted; in particular, the patient has had normal bowel movements without nausea or vomiting. She has been able to return to college and to pursue a moderately vigorous excercise programme. Of note, she re¬ ports a marked increase in gastric distress and perspiration whenever the SMS 201-995 infusion is interrupted for more than one h.
Discussion
The potent inhibitory effects of native somatosta¬ tin on GH secretion have been demonstrated in short term studies in acromegalie patients (Besser et al. 1974 
